Jazz Pharmaceuticals (JAZZ) Gross Margin (2010 - 2026)
Jazz Pharmaceuticals' quarterly Gross Margin came in at 87.45% in Q1 2026, down 89.0% year-on-year from 795.04% in Q1 2025, and little changed quarter-over-quarter from 87.18% in Q4 2025.
Jazz Pharmaceuticals has reported Gross Margin for 17 years, with the latest figure at 87.45% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin fell 89.0% year-over-year to 87.45%; the trailing twelve-month figure through Mar 2026 stood at 88.0% (down 81.0% YoY), and the FY2025 full-year result was 88.21%, down 84.0% from the prior year.
- Gross Margin for Q1 2026 stood at 87.45%, roughly flat from 87.18% in the prior quarter.
- The five-year high for Gross Margin was 89.81% in Q2 2023, with the low at 82.78% in Q4 2022.
- Average Gross Margin over 5 years is 87.77%, with a median of 88.35% recorded in 2025.
- Year-over-year, Gross Margin slumped 755 bps in 2022 and jumped 662 bps in 2023.
- Tracing JAZZ's Gross Margin over 5 years: stood at 82.78% in 2022, then advanced by 8 bps to 89.4% in 2023, then dropped by 1 bps to 88.17% in 2024, then declined by 1 bps to 87.18% in 2025, then advanced by 0 bps to 87.45% in 2026.
- The last three Gross Margin figures came in at 87.45% (Q1 2026), 87.18% (Q4 2025), and 88.56% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 82.22% |
| 10 | Jazz Pharmaceuticals | 14.35 Bn | 12.51 Bn | 934.80 Mn | 87.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 87.45% |
| Dec 31, 2025 | 87.18% |
| Sep 30, 2025 | 88.56% |
| Jun 30, 2025 | 88.88% |
| Mar 31, 2025 | 88.35% |
| Dec 31, 2024 | 88.17% |
| Sep 30, 2024 | 89.42% |
| Jun 30, 2024 | 89.27% |
| Mar 31, 2024 | 89.41% |
| Dec 31, 2023 | 89.40% |
| Sep 30, 2023 | 89.49% |
| Jun 30, 2023 | 89.81% |
| Mar 31, 2023 | 85.59% |
| Dec 31, 2022 | 82.78% |
| Sep 30, 2022 | 85.79% |
| Jun 30, 2022 | 86.69% |
| Mar 31, 2022 | 85.83% |
| Dec 31, 2021 | 84.82% |
| Sep 30, 2021 | 82.67% |
| Jun 30, 2021 | 84.15% |
| Mar 31, 2021 | 93.39% |
| Dec 31, 2020 | 92.46% |
| Sep 30, 2020 | 92.34% |
| Jun 30, 2020 | 94.27% |
| Mar 31, 2020 | 93.80% |
| Dec 31, 2019 | 93.92% |
| Sep 30, 2019 | 93.16% |
| Jun 30, 2019 | 92.81% |
| Mar 31, 2019 | 92.45% |
| Dec 31, 2018 | 94.47% |
| Sep 30, 2018 | 93.45% |
| Jun 30, 2018 | 92.19% |
| Mar 31, 2018 | 91.52% |
| Dec 31, 2017 | 94.21% |
| Sep 30, 2017 | 91.48% |
| Jun 30, 2017 | 91.53% |
| Mar 31, 2017 | 92.70% |
| Dec 31, 2016 | 91.51% |
| Sep 30, 2016 | 92.82% |
| Jun 30, 2016 | 93.17% |
| Mar 31, 2016 | 92.40% |
| Dec 31, 2015 | 92.95% |
| Sep 30, 2015 | 91.05% |
| Jun 30, 2015 | 92.97% |
| Mar 31, 2015 | 90.12% |
| Dec 31, 2014 | 91.22% |
| Sep 30, 2014 | 90.49% |
| Jun 30, 2014 | 88.73% |
| Mar 31, 2014 | 86.69% |
| Sep 30, 2013 | 88.79% |
| Jun 30, 2013 | 87.17% |
| Mar 31, 2013 | 85.32% |
| Dec 31, 2012 | 85.98% |
| Sep 30, 2012 | 80.62% |
| Jun 30, 2012 | 89.12% |
| Mar 31, 2012 | 91.40% |
| Dec 31, 2011 | 95.38% |
| Sep 30, 2011 | 94.60% |
| Jun 30, 2011 | 94.69% |
| Mar 31, 2011 | 94.48% |
| Dec 31, 2010 | 99.19% |
| Sep 30, 2010 | 93.21% |
| Jun 30, 2010 | 93.07% |